These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 28571522)
21. Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. Perales MA; Jenq R; Goldberg JD; Wilton AS; Lee SS; Castro-Malaspina HR; Hsu K; Papadopoulos EB; van den Brink MR; Boulad F; Kernan NA; Small TN; Wolden S; Collins NH; Chiu M; Heller G; O'Reilly RJ; Kewalramani T; Young JW; Jakubowski AA Bone Marrow Transplant; 2010 Sep; 45(9):1408-16. PubMed ID: 20062091 [TBL] [Abstract][Full Text] [Related]
22. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. Sweetenham JW; Pearce R; Taghipour G; Blaise D; Gisselbrecht C; Goldstone AH J Clin Oncol; 1996 Sep; 14(9):2465-72. PubMed ID: 8823324 [TBL] [Abstract][Full Text] [Related]
23. The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Kako S; Izutsu K; Kato K; Kim SW; Mori T; Fukuda T; Kobayashi N; Taji H; Hashimoto H; Kondo T; Sakamaki H; Morishima Y; Kato K; Suzuki R; Suzumiya J; Am J Hematol; 2015 Feb; 90(2):132-8. PubMed ID: 25382792 [TBL] [Abstract][Full Text] [Related]
24. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. Stiff PJ; Dahlberg S; Forman SJ; McCall AR; Horning SJ; Nademanee AP; Blume KG; LeBlanc M; Fisher RI J Clin Oncol; 1998 Jan; 16(1):48-55. PubMed ID: 9440722 [TBL] [Abstract][Full Text] [Related]
25. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A; J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703 [TBL] [Abstract][Full Text] [Related]
26. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168 [TBL] [Abstract][Full Text] [Related]
27. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. Sharp JG; Kessinger A; Mann S; Crouse DA; Armitage JO; Bierman P; Weisenburger DD J Clin Oncol; 1996 Jan; 14(1):214-9. PubMed ID: 8558200 [TBL] [Abstract][Full Text] [Related]
28. The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant. Wendland MM; Smith DC; Boucher KM; Asch JD; Pulsipher MA; Thomson JW; Shrieve DC; Gaffney DK Am J Clin Oncol; 2007 Apr; 30(2):156-62. PubMed ID: 17414465 [TBL] [Abstract][Full Text] [Related]
29. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH; Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607 [TBL] [Abstract][Full Text] [Related]
30. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314 [TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074 [TBL] [Abstract][Full Text] [Related]
32. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Osumi T; Mori T; Fujita N; Saito AM; Nakazawa A; Tsurusawa M; Kobayashi R Pediatr Blood Cancer; 2016 Oct; 63(10):1794-9. PubMed ID: 27314926 [TBL] [Abstract][Full Text] [Related]
33. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. Attarbaschi A; Dworzak M; Steiner M; Urban C; Fink FM; Reiter A; Gadner H; Mann G Pediatr Blood Cancer; 2005 Jan; 44(1):70-6. PubMed ID: 15368550 [TBL] [Abstract][Full Text] [Related]
34. Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. Shah NN; Ahn KW; Litovich C; Sureda A; Kharfan-Dabaja MA; Awan FT; Ganguly S; Gergis U; Inwards D; Karmali R; Lazaryan A; Lekakis L; Munshi P; Nathan S; Saad AA; Solh M; Steinberg A; Vij R; Wood WA; Fenske TS; Smith S; Hamadani M Blood Cancer J; 2019 Dec; 9(12):97. PubMed ID: 31796726 [TBL] [Abstract][Full Text] [Related]
35. Autologous stem cell transplantation and stem cell mobilization kinetics in elderly patients with B cell non-Hodgkin lymphoma. Dogu MH; Çagirgan S; Ocakci S; Kaya AH; Ilkkilic K; Sanli NM; Kahraman S; Eren R; Tekgunduz E; Hacioglu S; Kaynar L; Erkurt MA; Altuntas F Transfus Apher Sci; 2017 Dec; 56(6):814-818. PubMed ID: 29153347 [TBL] [Abstract][Full Text] [Related]
36. Allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomas: a retrospective analysis of 77 cases. Picleanu AM; Novelli S; Monter A; Garcia-Cadenas I; Caballero AC; Martino R; Esquirol A; Briones J; Sierra J Ann Hematol; 2017 May; 96(5):787-796. PubMed ID: 28168350 [TBL] [Abstract][Full Text] [Related]
37. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease. Schenkein DP; Dixon P; Desforges JF; Berkman E; Erban JK; Ascensao JL; Miller KB J Clin Oncol; 1994 Nov; 12(11):2423-31. PubMed ID: 7964959 [TBL] [Abstract][Full Text] [Related]
38. Stem cell transplantation for pediatric lymphoma: past, present and future. Bradley MB; Cairo MS Bone Marrow Transplant; 2008 Jan; 41(2):149-58. PubMed ID: 18084337 [TBL] [Abstract][Full Text] [Related]
39. Should children with non-Hodgkin lymphoma be treated with different protocols according to histopathologic subtype? Lee SH; Yoo KH; Sung KW; Ko YH; Lee JW; Koo HH Pediatr Blood Cancer; 2013 Nov; 60(11):1842-7. PubMed ID: 23857875 [TBL] [Abstract][Full Text] [Related]
40. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]